<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01407601</url>
  </required_header>
  <id_info>
    <org_study_id>EK 111/07</org_study_id>
    <nct_id>NCT01407601</nct_id>
  </id_info>
  <brief_title>Vitamin K2 Supplementation to Activate Matrix Gla Protein (MGP) as Endogenous Inhibitor of Vascular Calcification in Hemodialysis Patients</brief_title>
  <official_title>Food Supplementation With Vitamin K2 to Activate MGP as an Endogenous Inhibitor of Vascular Calcification in Hemodialysis Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>RWTH Aachen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>RWTH Aachen University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Vascular calcification (VC) is a predictor of cardiovascular morbidity and mortality.
      Hemodialysis (HD) patients suffer from severe vascular calcifications. Matrix Gla protein
      (MGP) is a central calcification inhibitor of the arterial wall and its activity depends on
      vitamin K-dependent γ-glutamate carboxylation. Noncarboxylated MGP, formed as a result of
      vitamin K deficiency, is associated with cardiovascular disease. Recent studies pointed
      towards poor vitamin K status in HD patients. We therefore aim to investigate whether daily
      vitamin K2 (MK-7) supplementation improves the bioactivity of vitamin K-dependent proteins in
      HD patients as assessed by circulating dephospho-noncarboxylated MGP (dp-ucMGP),
      noncarboxylated osteocalcin (ucOC) and noncarboxylated prothrombin (ucFII; PIVKA-II).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2008</start_date>
  <completion_date type="Actual">July 2009</completion_date>
  <primary_completion_date type="Actual">May 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Reduction of plasma levels of noncarboxylated MGP</measure>
    <time_frame>after 6 weeks of supplementation</time_frame>
    <description>Noncarboxylated MGP levels [pmol/L] will be determined from plasma samples by a non-commercial ELISA. Plasma samples will be obtained each week of the six-week treatment period and compared to baseline values.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Reduction of plasma levels of noncarboxylated osteocalcin</measure>
    <time_frame>after 6 weeks of supplementation</time_frame>
    <description>Noncarboxylated osteocalcin levels [ng/ml] will be determined from plasma samples by a commercial ELISA. Plasma samples will be obtained each week of the six-week treatment period and compared to baseline values.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Reduction of plasma levels of inactive prothrombin (PIVKA-II)</measure>
    <time_frame>after 6 weeks of supplementation</time_frame>
    <description>PIVKA-II levels [ng/ml] will be determined from plasma samples by a commercial ELISA. Plasma levels at the end of the six-week treatment period will be compared to baseline levels.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>increase of plasma levels of carboxylated MGP</measure>
    <time_frame>after 6 weeks of supplementation</time_frame>
    <description>Carboxylated MGP levels [pmol/L] will be determined from plasma samples by a non-commercial ELISA. Plasma samples will be obtained each week of the six-week treatment period and compared to baseline values.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>increase of plasma levels of carboxylated osteocalcin</measure>
    <time_frame>after 6 weeks of supplementation</time_frame>
    <description>Carboxylated MGP levels [ng/ml] will be determined from plasma samples by a commercial ELISA. Plasma samples will be obtained each week of the six-week treatment period and compared to baseline values.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">53</enrollment>
  <condition>CKD 5D, Hemodialysis</condition>
  <arm_group>
    <arm_group_label>45 µg MK-7</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>45 µg MK-7 daily over 6 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>135 µg MK-7</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>135 µg MK-7 daily over 6 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>360 µg MK-7</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>360 µg MK-7 daily over 6 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>daily supplementation of MK-7 over 6 weeks</intervention_name>
    <description>once daily intake of MK-7 prior to dialysis over 6 weeks</description>
    <arm_group_label>45 µg MK-7</arm_group_label>
    <arm_group_label>135 µg MK-7</arm_group_label>
    <arm_group_label>360 µg MK-7</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  &gt; 18 years of age

          -  minimum of 3 months of hemodialysis

          -  written consent

        Exclusion Criteria:

          -  chronic or acute bowel disease

          -  soy bean allergy

          -  active Vitamin K Supplementation

          -  oral anticoagulation with vitamin K Antagonists (coumarins)

          -  systemic therapy using steroids

          -  positive history for thrombosis or embolism

          -  pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ralf Westenfeld, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Clinic of the RWTH Aachen</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Georg Schlieper, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University Clinic of the RWTH Aachen</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Stefan Holzmann, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Dialysis Unit Erkelenz, Germany</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Stephan Heidenreich, MD</last_name>
    <role>Study Chair</role>
    <affiliation>KfH Dialysis Centre Aachen, Schurzelter Strasse</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Juergen Floege, MD</last_name>
    <role>Study Director</role>
    <affiliation>University Clinic of the RWTH Aachen</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Thilo Krueger, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University Hospital of the RWTH Aachen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>KfH Dialysis Unit Aachen</name>
      <address>
        <city>Aachen</city>
        <state>NRW</state>
        <zip>52074</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital of the RWTH Aachen</name>
      <address>
        <city>Aachen</city>
        <state>NRW</state>
        <zip>52074</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dialysis Unit Erkelenz</name>
      <address>
        <city>Erkelenz</city>
        <state>NRW</state>
        <zip>41812</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>August 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 29, 2011</study_first_submitted>
  <study_first_submitted_qc>August 1, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 2, 2011</study_first_posted>
  <last_update_submitted>August 1, 2011</last_update_submitted>
  <last_update_submitted_qc>August 1, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 2, 2011</last_update_posted>
  <responsible_party>
    <name_title>CTC Aachen</name_title>
    <organization>University Hospital of the RWTH Aachen</organization>
  </responsible_party>
  <keyword>vitamin K</keyword>
  <keyword>MK-7</keyword>
  <keyword>Hemodialysis</keyword>
  <keyword>vascular calcification</keyword>
  <keyword>Matrix Gla protein</keyword>
  <keyword>Osteocalcin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Calcinosis</mesh_term>
    <mesh_term>Vascular Calcification</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamins</mesh_term>
    <mesh_term>Vitamin K</mesh_term>
    <mesh_term>Vitamin K 2</mesh_term>
    <mesh_term>Vitamin MK 7</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

